Development of a non-invasive diagnostic microRNA test for endometriosis

Case Study

Endometriosis is an estrogen-dependent disease that results in pelvic pain and infertility. It is histologically characterized by the displacement of endometrial tissue to extrauterine locations. Laparoscopy remains the gold standard for the diagnosis of the condition. However, the invasive nature of surgery, coupled with the lack of a laboratory biomarker for the disease, results in a mean latency of 7-11 years from onset of symptoms to definitive diagnosis. Unfortunately, this delay in diagnosis may have significant consequences in terms of disease progression.

The team of prof. D’Hooghe at KU Leuven prioritized the discovery of a sensitive and specific microRNA biomarker for the nonsurgical detection of endometriosis. To this end, they called upon Biogazelle's biomarker development program. The performance of the resulting miRNA signatures was successfully confirmed in an independent patient cohort. These promising results warrant the further development of this non-invasive diagnostic test for clinical implementation, leading to earlier diagnosis and preventing disease progression to advanced stages.

"We decided to collaborate with Biogazelle because of their comprehensive expertise in miRNA expression analysis. Based on suggestions and recommendations from Biogazelle's experts we fine-tuned our project on miRNA biomarker discovery. The entire project proceeded as expected, in a pleasant cooperation and we could easily ask for advice and support with troubleshooting."

Dr Arne Vanhie, Department of Obstetrics and Gynaecology, KULeuven, Belgium


Learn what we can do for you

Subscribe to email updates